Overdose symptoms may include confusion, irritability, trouble thinking or concentrating, muscle weakness, or trouble breathing.
Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Magnesium oxide | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium oxide. |
| Sodium bicarbonate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Sodium bicarbonate. |
| Aluminum hydroxide | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminum hydroxide. |
| Calcium carbonate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Calcium carbonate. |
| Magaldrate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magaldrate. |
| Magnesium hydroxide | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium hydroxide. |
| Magnesium trisilicate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium trisilicate. |
| Magnesium carbonate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium carbonate. |
| Bismuth subnitrate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Bismuth subnitrate. |
| Magnesium silicate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium silicate. |
| Aluminium acetoacetate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium acetoacetate. |
| Hydrotalcite | The risk or severity of adverse effects can be increased when Tolevamer is combined with Hydrotalcite. |
| Magnesium peroxide | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium peroxide. |
| Almasilate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Almasilate. |
| Aluminium glycinate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium glycinate. |
| Aloglutamol | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aloglutamol. |
| Calcium silicate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Calcium silicate. |
| Aluminium phosphate | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium phosphate. |
| Thyrotropin alfa | Tolevamer can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Liothyronine | Tolevamer can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Tolevamer can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Liotrix | Tolevamer can cause a decrease in the absorption of Liotrix resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tiratricol | Tolevamer can cause a decrease in the absorption of Tiratricol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thyroid, porcine | Tolevamer can cause a decrease in the absorption of Thyroid, porcine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Digoxin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Deslanoside. |
| Ouabain | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Ouabain. |
| Digitoxin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digitoxin. |
| Oleandrin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Oleandrin. |
| Cymarin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Cymarin. |
| Proscillaridin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Lanatoside C. |
| Gitoformate | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Peruvoside. |
| Meloxicam | The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer. |
| Lithium citrate | The absorption of Lithium citrate can be decreased when combined with Tolevamer. |
| Lithium carbonate | The absorption of Lithium carbonate can be decreased when combined with Tolevamer. |
| Lithium hydroxide | The absorption of Lithium hydroxide can be decreased when combined with Tolevamer. |
| Cimetidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Cimetidine. |
| Nizatidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Nizatidine. |
| Ranitidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Ranitidine. |
| Famotidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Famotidine. |
| Methantheline | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Methantheline. |
| Metiamide | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Metiamide. |
| Roxatidine acetate | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Roxatidine acetate. |
| Lafutidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lafutidine. |
| Lavoltidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lavoltidine. |
| Niperotidine | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Niperotidine. |
| Pantoprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Pantoprazole. |
| Omeprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Omeprazole. |
| Lansoprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lansoprazole. |
| Esomeprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Esomeprazole. |
| Rabeprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Rabeprazole. |
| Dexlansoprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexlansoprazole. |
| Dexrabeprazole | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexrabeprazole. |
| Sodium zirconium cyclosilicate | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Sodium zirconium cyclosilicate. |
| Aluminium | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Aluminium. |
| Vonoprazan | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Vonoprazan. |
| Technetium Tc-99m oxidronate | Tolevamer may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent. |
| Tegoprazan | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Tegoprazan. |